- Home
- MRNO vs QURE Comparison
MRNO vs QURE Comparison
Compare MRNO & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNO
- QURE
- Stock Information
- Founded
- MRNO 2021
- QURE 1998
- Country
- MRNO United Kingdom
- QURE Netherlands
- Employees
- MRNO N/A
- QURE N/A
- Industry
- MRNO
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- MRNO
- QURE Health Care
- Exchange
- MRNO NYSE
- QURE Nasdaq
- Market Cap
- MRNO 794.8M
- QURE 750.6M
- IPO Year
- MRNO N/A
- QURE 2007
- Fundamental
- Price
- MRNO $9.52
- QURE $16.65
- Analyst Decision
- MRNO
- QURE Strong Buy
- Analyst Count
- MRNO 0
- QURE 8
- Target Price
- MRNO N/A
- QURE $30.43
- AVG Volume (30 Days)
- MRNO 4.5K
- QURE 4.6M
- Earning Date
- MRNO 12-31-2024
- QURE 11-05-2024
- Dividend Yield
- MRNO N/A
- QURE N/A
- EPS Growth
- MRNO N/A
- QURE N/A
- EPS
- MRNO N/A
- QURE N/A
- Revenue
- MRNO $24,458,160.00
- QURE $28,587,000.00
- Revenue This Year
- MRNO N/A
- QURE $150.65
- Revenue Next Year
- MRNO N/A
- QURE N/A
- P/E Ratio
- MRNO N/A
- QURE N/A
- Revenue Growth
- MRNO 296.23
- QURE N/A
- 52 Week Low
- MRNO $3.60
- QURE $3.73
- 52 Week High
- MRNO $38.00
- QURE $17.71
- Technical
- Relative Strength Index (RSI)
- MRNO 45.02
- QURE 78.10
- Support Level
- MRNO $9.53
- QURE $6.11
- Resistance Level
- MRNO $11.51
- QURE $17.71
- Average True Range (ATR)
- MRNO 0.96
- QURE 1.32
- MACD
- MRNO -0.17
- QURE 0.94
- Stochastic Oscillator
- MRNO 0.00
- QURE 88.41
About MRNO MURANO GLOBAL INVESTMENTS LIMITED
Murano Global Investments PLC is a real estate company that owns, develops, and invests in hotel, resort, and commercial properties throughout Mexico. Its portfolio includes the Andaz and Mondrian Hotels in Mexico City and Vivid Hotel Grand Island. The revenues are derived from the products and services provided to our customers such as Room rentals, Food and beverage, Private events, Spa services, and Other services.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.